1. Home
  2. SYBX vs RMCO Comparison

SYBX vs RMCO Comparison

Compare SYBX & RMCO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • SYBX
  • RMCO
  • Stock Information
  • Founded
  • SYBX N/A
  • RMCO 2021
  • Country
  • SYBX United States
  • RMCO United States
  • Employees
  • SYBX N/A
  • RMCO N/A
  • Industry
  • SYBX Biotechnology: Pharmaceutical Preparations
  • RMCO Multi-Sector Companies
  • Sector
  • SYBX Health Care
  • RMCO Miscellaneous
  • Exchange
  • SYBX Nasdaq
  • RMCO Nasdaq
  • Market Cap
  • SYBX 13.6M
  • RMCO 14.9M
  • IPO Year
  • SYBX N/A
  • RMCO N/A
  • Fundamental
  • Price
  • SYBX $1.20
  • RMCO $1.33
  • Analyst Decision
  • SYBX
  • RMCO
  • Analyst Count
  • SYBX 0
  • RMCO 0
  • Target Price
  • SYBX N/A
  • RMCO N/A
  • AVG Volume (30 Days)
  • SYBX 6.9K
  • RMCO 113.3K
  • Earning Date
  • SYBX 08-07-2025
  • RMCO 08-14-2025
  • Dividend Yield
  • SYBX N/A
  • RMCO 0.20%
  • EPS Growth
  • SYBX N/A
  • RMCO N/A
  • EPS
  • SYBX 0.21
  • RMCO N/A
  • Revenue
  • SYBX N/A
  • RMCO $1,568,212.00
  • Revenue This Year
  • SYBX N/A
  • RMCO N/A
  • Revenue Next Year
  • SYBX N/A
  • RMCO N/A
  • P/E Ratio
  • SYBX $5.92
  • RMCO N/A
  • Revenue Growth
  • SYBX N/A
  • RMCO 204.08
  • 52 Week Low
  • SYBX $0.90
  • RMCO $0.76
  • 52 Week High
  • SYBX $1.88
  • RMCO $1.88
  • Technical
  • Relative Strength Index (RSI)
  • SYBX 54.75
  • RMCO 52.78
  • Support Level
  • SYBX $1.18
  • RMCO $1.23
  • Resistance Level
  • SYBX $1.27
  • RMCO $1.54
  • Average True Range (ATR)
  • SYBX 0.05
  • RMCO 0.15
  • MACD
  • SYBX -0.00
  • RMCO 0.00
  • Stochastic Oscillator
  • SYBX 58.33
  • RMCO 20.29

About SYBX Synlogic Inc.

Synlogic Inc is a biopharmaceutical company focuses on rare metabolic disorders, with a lead program in phenylketonuria (PKU) and homocystinuria (HCU). The company's pipeline includes therapeutics for enteric hyperoxaluria, gout, and cystinuria. Using a proprietary approach, the company engineer GI-restricted, oral medicines from well-characterized probiotics. These drug candidates target specific biological pathways, leveraging Escherichia coli Nissle 1917 for consistency and safety. Engineered to be non-colonizing and reversible, the company offer oral administration, simplifying shipping and storage. The company operates in one segment-discovery and development of Synthetic Biotics-pioneering transformative treatments for serious diseases.

About RMCO Royalty Management Holding Corporation

Royalty Management Holding Corp formed to invest or purchase assets that have current or near-term income to provide the company with accretive cash flow from which it can reinvest in new assets or expand cash flow from existing assets. These assets typically are natural resources assets (including real estate and mining permits), patents, intellectual property, and emerging technologies.

Share on Social Networks: